A rare human TNFAIP3 variant reveals how A20 abundance is regulated by TAX1BP1

This study reveals that the abundance of the A20 protein is regulated by phosphorylation-dependent degradation via autophagy, a mechanism uncovered through the discovery of an epistatic interaction between a rare hypomorphic *TNFAIP3* variant and a *TAX1BP1* modifier that normally restrains A20 phosphorylation.

The Gist

The Big Picture: A Broken Brake and a Stuck Mechanic

Imagine your immune system is a high-speed race car. It needs to go fast to fight infections, but it also needs a reliable brake system to stop from crashing into itself (which causes autoimmune diseases like lupus or rheumatoid arthritis).

In this story, the brake is a protein called A20. Its job is to turn off the "fight" signal (called NF-kB) once the danger is gone. If you don't have enough A20, the car keeps speeding, crashes, and causes inflammation.

Scientists have long known that having less A20 causes disease. But they didn't know exactly how the body decides to throw away A20 or why sometimes the brake fails even when the body tries to fix it.

This paper tells the story of how two rare genetic "typos" in two different people helped scientists solve this mystery.

---

The Characters and the Plot

1. The First Typos: The "Sticky" Brake Pad (TNFAIP3 Variant)

The researchers looked at a group of patients with mysterious immune problems. They found a very rare genetic mutation in the TNFAIP3 gene (which makes the A20 brake).

• The Mutation: A tiny change in the protein's code (S254R).
• The Effect: This mutation made the A20 protein "sticky." It became prone to getting a chemical tag called phosphorylation.
• The Result: Think of phosphorylation as a "Do Not Use" sticker. In this case, the sticker was being put on the brake pad too often. Because the brake pad was covered in these stickers, the cell thought, "This brake is broken; throw it in the trash."
• The Outcome: The cell threw away the A20 brakes too quickly. Even though the patient had the gene to make the brakes, they didn't have enough working brakes left on the car.

2. The Second Typos: The Overzealous Mechanic (TAX1BP1 Variant)

Here is where it gets interesting. The patient with the "sticky" brake (A.II.1) had a much worse immune disease than other family members who had the same brake mutation. Why?

The scientists found a second mutation in a different gene called TAX1BP1.

• Who is TAX1BP1? Imagine TAX1BP1 as a mechanic or a garbage collector whose job is to inspect the brakes.
• Normal Job: Usually, the mechanic checks the brakes. If they are working fine, he leaves them alone. If they are broken, he helps recycle them.
• The Mutation (L307I): The patient had a slightly "super-charged" version of this mechanic.
• The Interaction: The "sticky" brake (A20) and the "super-charged" mechanic (TAX1BP1) loved to hug each other. The mutant mechanic grabbed the mutant brake even tighter than usual.

3. The Discovery: How the Body Throws Away Brakes

The scientists realized that the "Do Not Use" sticker (phosphorylation) wasn't just a signal that the brake was broken; it was actually a ticket to the trash can.

• The Old Theory: Scientists thought the body might chop up A20 using a specific enzyme (MALT1), like using a pair of scissors to cut a rope.
• The New Discovery: The paper shows that TAX1BP1 doesn't use scissors. Instead, it acts like a conveyor belt to the incinerator.
  • When A20 gets phosphorylated (stickered), TAX1BP1 grabs it.
  • TAX1BP1 then takes the A20 to a cellular recycling center called autophagy (think of this as a giant compost pile or incinerator).
  • The A20 is destroyed.

The Twist: The mutant mechanic (TAX1BP1L307I) was too good at his job. He grabbed the mutant brake (A20S254R) and sent it to the incinerator so fast that the patient ended up with almost no brakes at all. This explains why that specific patient was so sick compared to their family members who had the brake mutation but a normal mechanic.

The "Aha!" Moment

The paper solves a puzzle that had been confusing scientists for years:

1. Why does phosphorylation matter? We used to think phosphorylation just made the brake work better. This paper shows it actually makes the brake get destroyed.
2. Why do some people get sick and others don't? It's not just about having a broken gene; it's about the combination of genes. One person had a "sticky brake" and a "normal mechanic" (mild disease). Another had a "sticky brake" and a "super-charged mechanic" (severe disease).

The Takeaway

This research is like finding a missing piece of a car manual. It explains that the body has a sophisticated system for deciding when to throw away its own safety brakes.

• A20 is the brake.
• Phosphorylation is the "throw away" signal.
• TAX1BP1 is the garbage collector that listens to the signal.

When these two systems go wrong together, the immune system loses its brakes completely, leading to severe autoimmune disease. This discovery opens the door for new treatments: maybe in the future, doctors could give patients drugs that stop the "garbage collector" from throwing away the brakes, or stop the "stickers" from being put on them in the first place.

In short: The body doesn't just break the brakes; it actively recycles them when they get a specific chemical tag. And sometimes, a double-whammy of genetic mutations makes the recycling happen way too fast, leaving the immune system out of control.

Technical Summary

1. Problem Statement

• Context: Variants in the TNFAIP3 gene (encoding the protein A20) are strongly associated with human autoimmune diseases. A20 is a critical negative regulator of the NF-κB signaling pathway.
• The Paradox: While it is established that reduced A20 abundance (haploinsufficiency) causes autoinflammatory disease, the mechanisms regulating A20 protein levels post-transcriptionally remain poorly understood.
• Knowledge Gaps:
  • It is unclear how A20 phosphorylation (specifically at Ser381) affects its abundance, as previous studies suggested phosphorylation only enhanced its catalytic deubiquitinase activity.
  • Two known disposal pathways for A20 exist: MALT1-mediated proteolysis and p62-dependent autophagy, but no post-translational modifications have been definitively linked to targeting A20 for these pathways in disease states.
  • Mouse models with specific domain deletions (e.g., OTU domain) often fail to recapitulate the severe human autoimmune phenotypes, suggesting missing regulatory layers.

2. Methodology

The authors employed a human reverse genetics approach combined with molecular biology and cell biology techniques:

• Genetic Screening: Screened a cohort of patients with undiagnosed immune diseases for rare variants in immune-related genes.
• Patient Cohort: Identified a rare hypomorphic TNFAIP3 variant (p.Ser254Arg, or A20S254R) in five individuals across two kindreds. One proband (A.II.1) exhibited severe autoimmunity, while other carriers were less affected, suggesting a genetic modifier.
• Genomic Analysis: Performed Whole Exome Sequencing (WES), Sanger sequencing for validation, and transcriptomic analysis (RNA-seq/microarray) on sorted naïve B and T cells.
• In Silico & Structural Analysis: Used AlphaMissense, Polyphen2, and AlphaFold2 to predict variant pathogenicity and structural impact.
• Biochemical Assays:
  • In vitro Deubiquitination: Purified OTU domains to test catalytic activity on K48-linked polyubiquitin chains.
  • Cell Culture Models: Used HEK293 cells for transient transfection and NF-κB luciferase assays.
  • CRISPR/Cas9 Editing: Generated TNFAIP3 and TAX1BP1 double-knockout (DKO) Raji B cell lines, as well as TAX1BP1-deficient lines.
  • Immunoprecipitation (IP) & Western Blotting: Investigated protein-protein interactions (A20-TAX1BP1), phosphorylation status (pA20), and protein abundance under various conditions (TNF stimulation, nutrient starvation).
  • Pharmacological Inhibition: Used Bafilomycin A1 to inhibit autophagy and determine the degradation pathway.

3. Key Contributions

1. Identification of a Novel Hypomorphic Variant: Characterized the TNFAIP3 p.Ser254Arg (A20S254R) variant as catalytically impaired (reduced deubiquitinase activity) and prone to hyperphosphorylation.
2. Discovery of a Genetic Modifier: Identified a rare missense variant in the A20 binding partner TAX1BP1 (p.Leu307Ile) in the severely affected proband, establishing an epistatic interaction.
3. Mechanism of A20 Regulation: Demonstrated that A20 phosphorylation regulates protein abundance, not just catalytic activity. Phosphorylated A20 is targeted for degradation.
4. Role of TAX1BP1: Revealed that TAX1BP1 normally restrains A20 phosphorylation. The TAX1BP1 variant (L307I) enhances binding to phospho-A20, accelerating its disposal.
5. Pathway Specificity: Clarified that phosphorylation-dependent A20 turnover occurs via autophagy, not MALT1-mediated cleavage.

4. Key Results

• Characterization of A20S254R:

  • Located in the OTU domain near the catalytic triad.
  • Exhibits reduced deubiquitination activity compared to Wild-Type (WT).
  • Causes enhanced NF-κB activation in cells.
  • Crucially: The S254R mutation leads to hyperphosphorylation at Ser381, both at baseline and upon TNF stimulation.

• Clinical Phenotype & Modifier Search:

  • The proband (A.II.1) with A20S254R had severe autoimmunity (CVID, cytopenias), while other carriers had milder or no symptoms.
  • Transcriptomics of A.II.1 showed a strong NF-κB gain-of-function signature.
  • Screening for modifiers revealed a heterozygous TAX1BP1 variant (p.Leu307Ile) inherited from the father.

• TAX1BP1 Regulates A20 Phosphorylation:

  • In TAX1BP1-deficient cells, baseline levels of phospho-A20 (pA20) increased significantly, mimicking the activated state.
  • Co-expression experiments showed that WT TAX1BP1 reduces pA20 levels, whereas the TAX1BP1 L307I variant fails to do so, leading to accumulation of pA20.

• Phosphorylation Drives A20 Degradation:

  • The hyper-phosphorylated A20S254R variant has reduced protein abundance compared to WT.
  • A phospho-defective mutant (A20S381A) is more stable.
  • A double mutant (A20S254R/S381A) restores protein levels, confirming that the loss of A20S254R is due to phosphorylation-dependent turnover.

• Mechanism of Degradation (Autophagy vs. MALT1):

  • MALT1 Pathway: TAX1BP1 does not facilitate MALT1-mediated cleavage of A20.
  • Autophagy Pathway: In TAX1BP1-deficient cells, autophagy markers (LC3) were reduced and p62 increased.
  • Treatment with the autophagy inhibitor Bafilomycin A1 prevented the degradation of pA20.
  • Interaction: The TAX1BP1 L307I variant binds more strongly to the hyper-phosphorylated A20S254R, partitioning it toward the autophagy pathway for degradation.

5. Significance

• Novel Regulatory Mechanism: This study establishes that A20 abundance is dynamically regulated by phosphorylation-dependent autophagy, mediated by the adaptor protein TAX1BP1. This challenges the previous view that phosphorylation solely enhances A20 enzymatic activity.
• Explanation of Disease Paradox: It explains how a variant that increases phosphorylation (often thought to be activating) can lead to disease: the hyper-phosphorylation triggers rapid degradation of A20, resulting in a net loss of functional protein and uncontrolled NF-κB signaling.
• Epistasis in Autoimmunity: It highlights how rare variants in interacting partners (TAX1BP1) can modify the penetrance of primary disease-causing variants (TNFAIP3), explaining the heterogeneity in clinical phenotypes among carriers.
• Therapeutic Implications: Understanding that A20 stability is controlled by the TAX1BP1-phosphorylation-autophagy axis offers new potential targets for modulating NF-κB signaling in autoimmune diseases.

In summary, the paper uses a rare human genetic case to uncover a fundamental biological principle: TAX1BP1 acts as a "brake" on A20 phosphorylation; when this brake fails (due to TAX1BP1 mutation) or the substrate becomes hyper-phosphorylatable (due to TNFAIP3 mutation), A20 is rapidly degraded via autophagy, leading to autoimmunity.